NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
This announcement does not constitute a prospectus or offering memorandum or an offer in relation to any securities of
This announcement contains inside information for the purposes of the Market Abuse Regulation (EU No. 596/2014) ("MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain and shall therefore cease to be inside information.
(“First Sentinel” or the “Company”)
Alternative investment company
In conjunction with this, their partner company First Sentinel Corporate Finance has been appointed as Stabilitech’s fundraising advisor with respect to the current private capital raise.
Stabilitech is a
More than 50% of vaccines worldwide are lost because of cold-chain storage, as regular vaccines require storage conditions of -20 to -80C, which is extremely hard to maintain during transportation. What is unique about Stabilitech’s vaccine-in-a-capsule technology is that the capsules are thermally stable and thus can be transported at temperatures up to 50C.
After a successful safety animal trial, clinical trials are expected to start in June and the thermally stable oral vaccine could be available for distribution by the end of 2020.
The Company’s website is www.first-sentinel.com
For further corporate information, please contact:
Tel: + 44 (0) 7876 888 011
AQSE Corporate Advisor
Tel: +44(0)20 7628 3396